Dataset Information

A proteomics-based assessment of inflammation signatures in endotoxemia

ABSTRACT: The circulating proteome offers insight into the stage and severity of the immune response. To characterise the release kinetics and cellular source of plasma protein changes, serial samples were obtained from healthy volunteers (n=10, 3 time-points) injected with low-dose endotoxin (LPS) and analysed using date-independent acquisition (DIA) MS. The systemic and vascular inflammatory responses were compared using LPS-induced endotoxemia models in mice.

INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Blood Plasma, Aorta

DISEASE(S): Inflammation

SUBMITTER: Sean Burnap

LAB HEAD: Manuel Mayr

PROVIDER: PXD021077 | Pride | 2021-02-11

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Human_LPS_Top14_DepletedStorey_Plasma_120minDIA25mz_20180404_Sample02.raw	Raw
	Human_LPS_Top14_DepletedStorey_Plasma_120minDIA25mz_20180404_Sample03.raw	Raw
	Human_LPS_Top14_DepletedStorey_Plasma_120minDIA25mz_20180404_Sample04.raw	Raw
	Human_LPS_Top14_DepletedStorey_Plasma_120minDIA25mz_20180404_Sample06.raw	Raw
	Human_LPS_Top14_DepletedStorey_Plasma_120minDIA25mz_20180404_Sample07.raw	Raw

Items per page:

1 - 5 of 74

Publications

A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia.

Burnap Sean A SA Mayr Ursula U Shankar-Hari Manu M Cuello Friederike F Thomas Mark R MR Shah Ajay M AM Sabroe Ian I Storey Robert F RF Mayr Manuel M

Molecular & cellular proteomics : MCP 20210224

We have previously shown that multimers of plasma pentraxin-3 (PTX3) were predictive of survival in patients with sepsis. To characterize the release kinetics and cellular source of plasma protein changes in sepsis, serial samples were obtained from healthy volunteers (n = 10; three time points) injected with low-dose endotoxin (lipopolysaccharide [LPS]) and analyzed using data-independent acquisition MS. The human plasma proteome response was compared with an LPS-induced endotoxemia model in mi ...[more]

PMID: 33288685

Similar Datasets

Project description:Aims: A mutation in the phospholamban (PLN) gene, leading to deletion of Arg14 (R14del), has been associated with malignant arrhythmias and ventricular dilation. Identifying pre-symptomatic carriers with vulnerable myocardium is crucial because arrhythmia can result in sudden cardiac death, especially in young adults with PLN-R14del mutation. This study aimed at assessing the efficiency and efficacy of in vivo genome editing, using CRISPR/Cas9 and a cardiotropic adeno-associated virus (AAV9), in improving cardiac function in young adult mice expressing the human PLN-R14del. Methods and Results: Humanized mice were generated expressing human wild-type (hPLN-WT) or mutant (hPLN-R14del) PLN in the heterozygous state, mimicking human carriers. Cardiac magnetic resonance imaging at 12 weeks of age showed bi-ventricular dilation and increased stroke volume in mutant vs. WT mice, with no deficit in ejection fraction or cardiac output. Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachycardia (VT) in hPLN-R14del relative to hPLN-WT. Specifically, the VT threshold was significantly reduced (20.3±1.2 Hz in hPLN-R14del vs. 25.7±1.3 Hz in WT, p<0.01) reflecting higher arrhythmia burden. To inactivate the R14del allele, mice were tail-vein-injected with AAV9.CRISPR/Cas9/gRNA or AAV9 empty capsid (controls). CRISPR-Cas9 efficiency was evaluated by droplet digital PCR and NGS-based amplicon sequencing. In vivo gene editing significantly reduced end diastolic and stroke volumes in hPLN-R14del CRISPR-treated mice compared to controls. Susceptibility to VT was also reduced, as the VT threshold was significantly increased relative to controls (30.9±2.3 Hz vs. 21.3±1.5 Hz; p<0.01). Conclusions: This study is the first to show that disruption of hPLN-R14del allele by AAV9- CRISPR/Cas9 improves cardiac function and reduces VT susceptibility in humanized PLN-R14del mice, offering preclinical evidence for translatable approaches to therapeutically suppress the arrhythmogenic phenotype in human patients with PLN-R14del disease.